ANKRD20A17P

Across TCGA pan-cancer cohorts, ANKRD20A17P RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated ANKRD20A17P data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANKRD20A17P RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKRD20A17P expression acts as an unfavorable survival marker, although some lineages such as LUAD and BLCA show a favorable association.

LUAD, READ, and UCEC are the cancer types where ANKRD20A17P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.774	0.334	<.001	78	view →
READ	DFS	Tertile	II,III,IV	0.447	0.826	<.001	51	view →
UCEC	OS	Tertile	All	0.294	0.725	<.001	48	view →
STAD	DFS	Tertile	II,III,IV	0.183	0.445	.007	37	view →
LIHC	OS	Median	All	0.696	0.820	.002	20	view →
KICH	OS	Quartile	All	0.778	0.975	.013	19	view →
KIRC	DFS	Tertile	IV	0.303	0.658	.019	18	view →
BLCA	OS	Quartile	III,IV	0.595	0.338	.005	17	view →
SKCM	OS	Tertile	All	0.420	0.248	.004	12	view →
PCPG	OS	Tertile	All	0.898	1.000	.008	10	view →
DLBC	DFS	Tertile	All	0.552	0.843	.034	9	view →
KIRP	DFS	Tertile	All	0.849	0.933	.022	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

ANKRD20A17P–LUAD (DFS)

Open the LUAD breakdown →